Dr. Ryan Harris

Board Member

Ryan brings to Norwest Venture Partners more than twenty-five years of healthcare experience and eighteen years as a growth equity and buyout investor. Combining deep medical knowledge and extensive strategic business experience, Ryan focuses on growth equity investments in the healthcare sector in Norwest’s Palo Alto office. Areas in which he invests include healthcare services, pharma services, healthcare IT, medical devices. Ryan’s current investments include American Endovascular, Blue Cloud, Gateway Learning Group, Onsite Dental, Rivermend Health, and TARGET PharmaSolutions. His previous investments include Capsugel (acquired by Lonza), Crossover Health (acquired by Gurnet Point Capital), and iCardiac (acquired by ERT).

Prior to joining Norwest, Ryan was a Principal with The Carlyle Group and a Venture Partner with Industry Ventures, where he focused on large cap buyouts to growth equity and venture. At Carlyle, Ryan’s deals led to realized profitable exits of more than $2.2 billion equity value. He served as a member or observer on the Board of Directors of Align Technologies (Nasdaq: ALGN), AqueSys, Colin Medical, ConnectiCare, MedPointe Pharmaceuticals, Multiplan, NeoVista, and Qualicaps. At Industry Ventures, Ryan executed transactions involving Access Closure, Cardiofocus, Ingenuity, and Intarcia.

Prior to joining Carlyle, Ryan was a consultant in the West Coast Healthcare Practice of McKinsey & Company, where he worked with a variety of biotechnology, pharmaceutical and medical device companies on corporate, R&D and marketing strategies.

Ryan has authored more than 25 peer-reviewed comparative effectiveness articles in JAMA, Lancet, Annals of Internal Medicine, the Journal of Health Economics, and others.

Ryan holds an M.D. from the University of California, San Francisco, School of Medicine, a M.S. in health research and policy, and a B.A. in psychology from Stanford University. Ryan also attended Oxford University’s Magdalen College.